by jtcir-auto | Mar 25, 2021 | Press Releases
– Company executing on growth strategy to build-out pipeline of development assets- Pivotal Phase 3 safety and efficacy study AEZS-130-P02 (“Study P02”) expected to commence in Q2 2021- Strong balance sheet enables significant optionality for growth...
by jtcir-auto | Mar 25, 2021 | Press Releases
– Company executing on growth strategy to build-out pipeline of development assets- Pivotal Phase 3 safety and efficacy study AEZS-130-P02 (“Study P02”) expected to commence in Q2 2021- Strong balance sheet enables significant optionality for growth...
by jtcir-auto | Mar 22, 2021 | Press Releases
CHARLESTON, S.C., March 22, 2021 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests,...
by jtcir-auto | Mar 22, 2021 | Press Releases
CHARLESTON, S.C., March 22, 2021 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests,...
by jtcir-auto | Mar 15, 2021 | Press Releases
– Company secures next step to continue to build-out pipeline of assets- Company exercised its option to enter into an exclusive license of intellectual property for the development of a proprietary and orally active bacterial vaccine platform technology...